Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;18(10):2503-2512.
doi: 10.1111/jth.15009. Epub 2020 Sep 11.

Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura

Affiliations

Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura

X Long Zheng et al. J Thromb Haemost. 2020 Oct.

Abstract

Background: Despite advances in treatment options for thrombotic thrombocytopenic purpura (TTP), there are still limited high quality data to inform clinicians regarding its management.

Methods: In June 2018, the ISTH formed a multidisciplinary guideline panel to issue recommendations about treatment of TTP. The panel discussed 12 treatment questions related to both immune-mediated TTP (iTTP) and hereditary/congenital TTP (cTTP). The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including evidence-to-decision frameworks, to appraise evidence and formulate recommendations.

Results: The panel agreed on eleven recommendations based on evidence ranging from very low to moderate certainty. For first episode and relapses of acute iTTP, the panel made a strong recommendation for the addition of corticosteroids to therapeutic plasma exchange (TPE), and a conditional recommendation for addition of rituximab and caplacizumab. For asymptomatic iTTP with low ADAMTS13, the panel made a conditional recommendation for rituximab outside of pregnancy, and for prophylactic TPE during pregnancy. For asymptomatic cTTP, the panel made a strong recommendation for prophylactic plasma infusion during pregnancy, but a conditional recommendation for plasma infusion or a wait and watch approach outside of pregnancy.

Conclusions: The panel's recommendations are based on all the available evidence for the treatment effects of various approaches including suppressing inflammation, blocking platelet clumping, replacing the missing and/or inhibited ADAMTS13, and suppressing ADAMTS13 antibody production. There was insufficient evidence for further comparison of different treatment approaches, for which future high-quality studies in iTTP (e.g., rituximab, corticosteroids, recombinant ADAMTS13, and caplacizumab) and in cTTP (eg, recombinant ADAMTS13) are needed.

Keywords: TTP; diagnosis; good practice; guidelines; management.

PubMed Disclaimer

Similar articles

  • ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.
    Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. Zheng XL, et al. J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11. J Thromb Haemost. 2020. PMID: 32914526 Free PMC article.
  • 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.
    Zheng XL, Al-Housni Z, Cataland SR, Coppo P, Geldziler B, Germini F, Iorio A, Keepanasseri A, Masias C, Matsumoto M, McCrae KR, McIntyre J, Mustafa RA, Peyvandi F, Russell L, Tarawneh R, Vesely SK; International Society on Thrombosis and Haemostasis. Zheng XL, et al. J Thromb Haemost. 2025 Jun 17:S1538-7836(25)00360-5. doi: 10.1016/j.jtha.2025.06.002. Online ahead of print. J Thromb Haemost. 2025. PMID: 40533296
  • Immune Thrombotic Thrombocytopenic Purpura: A Review.
    Pishko AM, Li A, Cuker A. Pishko AM, et al. JAMA. 2025 Aug 12;334(6):517-529. doi: 10.1001/jama.2025.3807. JAMA. 2025. PMID: 40388146 Review.
  • ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura.
    Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. Zheng XL, et al. J Thromb Haemost. 2020 Oct;18(10):2486-2495. doi: 10.1111/jth.15006. Epub 2020 Sep 11. J Thromb Haemost. 2020. PMID: 32914582 Free PMC article.
  • Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025.
    Azoulay E, Veyradier A, Cataland S, Joly BS, Knoebl P, Zafrani L, Wendon J, Fakhouri F, Lämmle B, Pavenski K, Biebuyck N, Vanhoorelbeke K, Chaturvedi S, Pishko AM, Donadello K, Scully M, Matsumoto M, Peyvandi F, Mingot-Castellano ME, Zheng XL, Mariotte E, Benhamou Y, Coppo P. Azoulay E, et al. Intensive Care Med. 2025 Jul;51(7):1225-1239. doi: 10.1007/s00134-025-07981-3. Epub 2025 Jul 3. Intensive Care Med. 2025. PMID: 40608084 Review.

Cited by

References

    1. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–397. - PubMed
    1. Bell WR, Braine HG, Ness PM, Kickler TS. Improved Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398–403. - PubMed
    1. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043–4049. - PMC - PubMed
    1. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129:2836–2846. - PubMed
    1. Staley EM, Cao W, Pham HP, et al. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. Haematologica. 2019;104:166–175. - PMC - PubMed

Publication types

MeSH terms